GlassScriptPhysician profile
James K Jung
NPI 1649224999
$2,926.42
in general payments reported to CMS, 2019-2025
26 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $492 · 2021: $468 · 2022: $92.36 · 2023: $451 · 2024: $565 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,450.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $826.08 | 2019-2025 | Grafix, Collagenase Santyl, Stravix |
| Zimmer Biomet Holdings, INC. | $624.89 | 2019-2022 | |
| Stryker Corporation | $536.63 | 2019-2025 | Prostep, Prostep Mica, Citrefix |
| Linvatec Corporation | $202.53 | 2024-2025 | Biobrace 23mm, 5ms, In2bones USA |
| Biotissue Holdings INC. | $101.07 | 2023 | |
| Davol INC. | $66.66 | 2019 | |
| Conmed Corporation | $56.46 | 2023 | 5ms |
| Mimedx Group, INC. | $51.83 | 2024-2025 | |
| Organogenesis INC. | $50.15 | 2021-2024 | |
| Gilead Sciences, INC. | $45.45 | 2021-2022 | |
| Treace Medical Concepts, INC. | $43.76 | 2024-2025 | |
| Averitas Pharma INC. | $36.17 | 2023 | Qutenza |
| Ibsa Pharma INC. | $31.77 | 2023 | Tirosint, Licart |
| Tactile Systems Technology INC | $29.61 | 2021 | |
| Abbvie INC. | $29.48 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $23.55 | 2021 | |
| Heron Therapeutics, INC. | $22.75 | 2021 | |
| Wright Medical Technology, INC. | $20.79 | 2019 | |
| Merck Sharp & Dohme LLC | $19.80 | 2019 | |
| Melinta Therapeutics, LLC | $17.70 | 2020 | |
| Paratek Pharmaceuticals, INC. | $17.34 | 2025 | Nuzyra |
| Almatica Pharma LLC | $17.29 | 2021 | |
| Depuy Synthes Sales INC. | $17.13 | 2023 | Motoband, Minibunion, Hammerlock |
| Integra Lifesciences Corporation | $14.01 | 2019 | |
| Djo, LLC | $11.86 | 2020 | |
| Horizon Therapeutics Plc | $11.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.